🕒 Last update: loading…21/11/2026

Stock Ardelyx, Inc. ARDX

Ardelyx, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ✅ Price trend passed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 320.11%

Price change 2019 → 2020: -13.83%

Price change 2020 → 2021: -32.10%

Price change 2021 → 2022: 159.09%

Price change 2022 → 2023: 117.54%

Price change 2023 → 2024: -18.23%

Price change 2024 → 2025: 14.99%

Price change 2025 → 2026: -48.03%

Price change 2026 (year to date): -50.73%

Financial growth

Revenue CAGR (8 years): 105.78%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 1.27

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -14.16

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 58.49% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Ardelyx, Inc.–1.27+39.4 %🔒
Pharming Group N.V.40.00.42+50.2 %–
4D Molecular Therapeutics, Inc.–0.04+40.0 %–
Xvivo Perfusion AB (publ)50.10.06+36.1 %–
Lumibird S.A.39.90.71+9.8 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Ardelyx, Inc. over the latest fiscal years.

Revenue
407 m USD
fiscal year 2025
Net income
-61.6 m USD
fiscal year 2025
Net margin
-15.1 %
fiscal year 2025
Average annual growth
+121.9 %
Revenue growth over 5 years
Average annual growth
+32.7 %
Revenue growth over 10 years
Market cap
777 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20207.6 m-94.3 m-1,245.7 %n/a
202110.1 m-158 m-1,566.5 %+33.4 %
202252.2 m-67.2 m-128.8 %+416.6 %
2023124 m-66.1 m-53.1 %+138.6 %
2024334 m-39.1 m-11.7 %+168.1 %
2025407 m-61.6 m-15.1 %+22.1 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Ardelyx, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-0.01
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-7.32 x
net cash
Fiscal year20212022202320242025
Cash and investments117 m124 m184 m250 m265 m
Total Debt45.5 m36.5 m56.0 m153 m212 m
Net Debt-26.9 m-59.7 m34.5 m88.5 m144 m
Equity82.6 m98.3 m167 m173 m167 m
Total assets150 m190 m298 m436 m502 m
Operating cash flow-153 m-70.0 m-89.7 m-44.8 m-42.5 m
Investments (capex)1.9 m55,000344,0001.0 m1.5 m
Free cash-flow-154 m-70.1 m-90.1 m-45.8 m-44.0 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-13.62 x
Price / book value4.66 x
Return on Equity (ROE)-35.3 %
Return on Invested Capital (ROIC)-7.8 %
Net margin-11.8 %
Debt / equity1.56 x
Current ratio3.45 x
Interest coverage-1.35 x
Free cash-flow yield-2.1 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Ardelyx, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
16 analysts

Breakdown of ratings

strong buy 0buy 16hold 0sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Ardelyx, Inc.

Large funds tracked
20
hold the stock as of 2026Q2
Executives (insiders)
0 / 22
0 purchases, 22 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street26.7 m136 m0.0 %+96.4 %2026Q2
BlackRock23.5 m120 m0.0 %+11.1 %2026Q2
Vanguard Group19.0 m111 m0.0 %+3.3 %2025Q4
Millennium Management13.9 m70.9 m0.1 %-22.1 %2026Q2
Geode Capital Management6.4 m32.7 m0.0 %+6.6 %2026Q2
Two Sigma Investments5.2 m26.6 m0.0 %+21.9 %2026Q2
Goldman Sachs3.7 m18.8 m0.0 %+14.6 %2026Q2
Morgan Stanley2.4 m12.2 m0.0 %+39.8 %2026Q2

Latest insider transactions

DatePersonSideAmount
21/08/2026Hohenleitner Susansale6,009 USD
21/08/2026Reilly Joseph Jamessale11,077 USD
21/08/2026Reilly Joseph Jamessale4,281 USD
21/08/2026Bishop John Esale66,651 USD
21/08/2026Bishop John Esale9,523 USD
21/08/2026Brady James Parkersale7,621 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 19/06/2014
ISIN code
US0396971071
Workforce
395
full-time employees
Chief executive
Michael G. Raab

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Ardelyx, Inc.

What is the Ardelyx, Inc. share price?

Latest recorded price: 3.09 USD on 13/11/2026, for a market cap of 777 m USD.

What is the revenue of Ardelyx, Inc.?

407 m USD for fiscal year 2025, with net income of -61.6 m USD (net margin -15.1 %).

What do analysts say about Ardelyx, Inc.?

Out of 16 analysts: 16 buy or strong buy, 0 hold, 0 sell or strong sell.

Is Ardelyx, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0396971071).

How many employees does Ardelyx, Inc. have?

395 full-time employees according to the latest published profile.

Who runs Ardelyx, Inc.?

Michael G. Raab is the company's chief executive.

Which large funds own Ardelyx, Inc.?

As of 2026Q2, among the large funds tracked: State Street, BlackRock, Vanguard Group, Millennium Management, Geode Capital Management.

07

Similar stocks